Immunomedics (IMMU) Reports New Antibody for Pretargeted Imaging and Therapy of Colorectal Cancer
Immunomedics, Inc. (Nasdaq: IMMU) reported that TF2, a proprietary pretargeting antibody, produced tumor-specific PET imaging and prolonged survival in a human colorectal cancer model. Results from two studies were presented at the 56th annual meeting of the Society of Nuclear Medicine.
TF2 is an antibody constructed using the Company's proprietary protein engineering platform technology, called Dock-and-Lock (DNL). It specifically targets the carcinoembryonic (CEA or CEACAM5) antigen expressed in many human cancers, including colorectal cancer. Unlike conventional antibodies which can only attach to one receptor, TF2 has been modified to contain an additional binding site that recognizes a radioisotope-carrying peptide. This allows the separate administration of TF2 before the delivery of radioisotope, a concept known as pretargeting, which is developed by the Company's majority-owned subsidiary, IBC Pharmaceuticals, Inc. [SM]
Create E-mail AlertRelated Categories
Corporate NewsStocks Mentioned
+0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
